Clinical trials: Hepatobiliary Disorders
Liver Disease
Hepatic Impairment Study
This study is to find out how the subject's body processes and reacts to the study drug, and to find out how long it remains in the subjects system after one dose.
- Trial name
- NCT00829231
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Where
- 3 sites in United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Bayer
Nonalcoholic Steatohepatitis (NASH)
A Study of BOS-580 in Obese Subjects at Risk for, or With Biopsy-confirmed, Nonalcoholic Steatohepatitis (NASH) With an Extension
This is a randomized, blinded, placebo-controlled study of Efimosfermin in obese participants at risk for, or with biopsy-confirmed, nonalcoholic steatohepatitis (NASH), with a single arm open-label extension.
- Trial name
- NCT04880031
- Testing
- Efimosfermin
- Where
- 48 sites in United States
- Volunteers
- 231 people
- Sponsor
- GlaxoSmithKline
Metabolic Dysfunction-Associated Steatohepatitis (MASH), Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)
A Single-Ascending and Repeated Dose Study of LY3849891 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
The main purpose of this study is to evaluate the safety and tolerability of the study drug LY3849891 in participants with metabolic dysfunction-associated steatotic liver disease (MASLD) who have the patatin-like phospholipase…
- Trial name
- NCT05395481
- Testing
- LY3849891
- Where
- 16 sites in United States, Japan and 1 more
- Volunteers
- 115 people
- Sponsor
- Eli Lilly and Company
Liver Disease Chronic, End Stage Liver DIsease
LiverPAL: A Trial of Inpatient Palliative Care for Patients With Advanced Liver Disease
The goal of this clinical trial is to evaluate whether early integration of palliative care in the care of hospitalized patients with advanced liver disease (AdvLD) can improve patients' quality of life, physical symptoms, mood…
- Conditions
- Liver Disease Chronic, End Stage Liver DIsease, Cirrhosis, Cirrhosis, Liver
- Trial name
- LiverPAL (NCT05998330)
- Testing
- LiverPAL
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Massachusetts General Hospital
Locally Advanced Cancer, Metastatic Cancer
Identification of In-hospital Patients in Need of Palliative Care Using a New Simplified Screening Tool
Every day many patients affected by chronic life-limiting illnesses are admitted into Internal Medicine wards, coming from the Emergency Department.
- Conditions
- Locally Advanced Cancer, Metastatic Cancer, Chronic Respiratory Failure, Chronic Heart Failure
- Trial name
- SST2017 (NCT04143230)
- Testing
- Screening for PC by means of two different screening tools
- Where
- Italy
- Volunteers
- 660 people
- Sponsor
- A.O.U. Città della Salute e della Scienza
Non-Alcoholic Fatty Liver Disease
Probiotics in NASH Patients - PROBILIVER TRIAL
Non-alcoholic Fatty Liver Disease (NAFLD) is characterized by excessive accumulation of lipids in hepatocytes, not associated with alcohol consumption and ranges from hepatic steatosis to steatohepatitis, a form that can progress…
- Trial name
- NASH (NCT03467282)
- Testing
- Probiotic
- Where
- Brazil
- Volunteers
- 46 people
- Sponsor
- Hospital de Clinicas de Porto Alegre
Cirrhosis and Chronic Liver Disease
Sugammadex Versus Neostigmine in Patients With Liver Cirrhosis Undergoing Liver Resection
Liver cirrhosis is a progressive disease characterized by loss of functional hepatocytes that substantially affects drug pharmacokinetics.
- Trial name
- NCT02414880
- Testing
- Sugammadex, Neostigmine, Rocuronium
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Cairo University
NAFLD
Prediction of Severity of Liver Disease Non Alcoholic Fatty Liver Disease in Patients With Suspected NAFLD by a 13C Octanoate Breath Test
The Exalenz clinical investigation is a multicenter, non-randomized, blinded, study of the ¹³C-Octanaote breath test (OBT). The OBT is a non-invasive test for evaluation of disease severity in patients with suspected non…
- Trial name
- NCT01281059
- Testing
- BreathID - Breath Test - 13C Octanoate
- Where
- Israel
- Sponsor
- Hadassah Medical Organization
Hepatic Impairment, Cirrhosis
Hepatic Impairment With Cirrhosis Due to Cholestatic Liver Disease
A Phase 1, Open-label Extension Groups Study in Subjects having Hepatic Impairment with Cirrhosis due to Cholestatic Liver Disease
- Conditions
- Hepatic Impairment, Cirrhosis, Cholestatic Liver Disease
- Trial name
- NCT05045482
- Testing
- Saroglitazar Magnesium 1 mg, Saroglitazar Magnesium 2 mg
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Zydus Therapeutics Inc.
Nonalcoholic Fatty Liver Disease
Effectiveness of Exercise Applications on Hepatic Steatosis and Physical Fitness in Patients With NAFLD
Purpose of the study will investigate the effects of two different training programs on hepatic steatosis and physical fitness parameters.
- Trial name
- NCT03461562
- Testing
- Aerobic Exercise
- Where
- Turkey (Türkiye)
- Volunteers
- 31 people
- Sponsor
- Okan University
Porto-sinusoidal Vascular Liver Disorder, Liver Cirrhosis
Multiparametric Ultrasound for the Noninvasive Diagnosis of Porto-sinusoidal Vascular Liver Disorder
Porto-sinusoidal vascular disease (PSVD) is a rare clinical entity characterized by significant portal hypertension in the absence of cirrhosis on liver histology, which may or may not show specific alterations of the portal…
- Conditions
- Porto-sinusoidal Vascular Liver Disorder, Liver Cirrhosis, Portal Hypertension, Noncirrhotic, Portal Hypertension Related to Cirrhosis
- Trial name
- CEUS-PSVD (NCT07492862)
- Testing
- Evaluation of quantitative perfusion parameters at dynamic contrast-enhanced ultrasound through Vuebox Software
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Compensated Advanced Chronic Liver Disease, Portal Hypertension
The Precise Selection of Stent Diameter for Portal Hypertension Patients With TIPS
The precise planning of TIPS, especially individual selection of stent diameter, is a hot and difficult topic in the field. We have successfully developed a non-invasive technology to evaluate hepatic venous pressure gradient and…
- Trial name
- NCT04421118
- Testing
- a non-invasive technology to evaluate hepatic venous pressure gradient and portal pressure gradient
- Where
- China
- Volunteers
- 60 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Steatotic Liver Disease
Steatotic Liver Disease in Austria - Prospective Registry With Biobank
Steatotic liver disease (SLD) is the most common chronic liver disease and is associated with an increased risk of liver-related complications, cardiovascular disease, and malignancies.
- Trial name
- SLD-AT (NCT07914582)
- Where
- Austria
- Volunteers
- 20,000 people
- Sponsor
- Medical University of Vienna
Non-Alcoholic Fatty Liver Disease
Super HEROES: Searching How the Extract Rebaudioside Occludes Excess Steatosis
In order to determine whether rebaudioside consumption can be used as a treatment for adolescents with Non-alcoholic Fatty Liver Disease (NAFLD) by demonstrating a decrease in alanine aminotransferase (ALT) levels participants…
- Trial name
- NCT03985020
- Testing
- Stevia Intervention, Water Intervention
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Children's Hospital Los Angeles
Morbid Obesity, Type2diabetes
Comorbidities Resolution After MGB Surgery and Change in Body Composition
This observational study aims to learn about the correlation between the improving comorbidities associated with obesity after MGB (Mini-Gastric Bypass) surgery and changes in body composition in morbidly obese patients.
- Conditions
- Morbid Obesity, Type2diabetes, Sleep Apnea, Hypothyroidism
- Trial name
- MOGAMBO (NCT06015620)
- Testing
- Mini gastric bypass surgery
- Where
- India
- Volunteers
- 35 people
- Sponsor
- All India Institute of Medical Sciences, Bhubaneswar
Non-Alcoholic Fatty Liver Disease
The Effect of Bariatric Surgery on Hepatic Metabolism in Non-Alcoholic Fatty Liver Disease
The purpose of this study is to investigate the mechanisms underlying bariatric surgery-induced resolution of non-alcoholic fatty liver disease.
- Trial name
- BASIC (NCT05551559)
- Testing
- bariatric surgery
- Where
- Finland
- Volunteers
- 180 people
- Sponsor
- Helsinki University Central Hospital
Alcoholic Cirrhosis
Alcohol Biomarker Study
Objective: To validate ethyl glucuronide in scalp hair, fingernail and urine as a biomarker for alcohol use in patients with alcoholic cirrhosis.
- Trial name
- NCT04363424
- Where
- Netherlands
- Volunteers
- 191 people
- Sponsor
- Maastricht University Medical Center
Fatty Liver Disease
Effect of Thyroid Disorders in Liver Diseases
Aims of the Research 1. To detect correlation between hyperthyroidism and non alcoholic fatty liver disease (NAFLD). 2. To detect hepatic risk in subclinical and clinical hypothyroidism . 3.
- Trial name
- NCT06071923
- Testing
- Fibroscan
- Volunteers
- 140 people
- Sponsor
- Assiut University
Chronic Liver Disease, Thyroid Disease
The Development of Quantitative Ultrasound Imaging Software Platform
The goal of this observational study is to compare the image differences between conventional ultrasound and artificial intelligence-based ultrasound software in conscious adults.
- Conditions
- Chronic Liver Disease, Thyroid Disease, Benign Breast Disease, Malignant Breast Neoplasm
- Trial name
- NCT05836246
- Where
- South Korea
- Volunteers
- 196 people
- Sponsor
- Seoul National University Bundang Hospital
Nonalcoholic Steatohepatitis, Osteoarthritis
FTIH Study of ECC0509 in Healthy Volunteers
A Phase 1, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Single And Multiple Ascending Dose, First-Time-In-Human Study to Assess The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ECC0509 in…
- Trial name
- NCT05012423
- Testing
- ECC0509
- Where
- Australia
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Eccogene
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.